Q2 EPS Estimate for Cardiff Oncology Decreased by Analyst

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Investment analysts at Noble Financial dropped their Q2 2026 earnings per share estimates for Cardiff Oncology in a report issued on Friday, May 22nd. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings of ($0.20) per share for the quarter, down from their prior estimate of ($0.15). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.65) per share. Noble Financial also issued estimates for Cardiff Oncology’s Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.78) EPS.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.09 million. Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%.

A number of other research analysts also recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Piper Sandler lowered their price target on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Monday, May 18th. Finally, Wall Street Zen downgraded Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.10.

Cardiff Oncology Trading Up 9.0%

Shares of CRDF opened at $1.94 on Wednesday. The company’s fifty day simple moving average is $1.70 and its 200 day simple moving average is $2.06. Cardiff Oncology has a 1-year low of $1.48 and a 1-year high of $4.56. The company has a market cap of $132.64 million, a price-to-earnings ratio of -2.90 and a beta of 1.36.

Hedge Funds Weigh In On Cardiff Oncology

Institutional investors and hedge funds have recently made changes to their positions in the company. Glenview Trust co boosted its stake in Cardiff Oncology by 79.9% in the 2nd quarter. Glenview Trust co now owns 43,128 shares of the company’s stock valued at $136,000 after purchasing an additional 19,150 shares during the period. Virtu Financial LLC bought a new position in Cardiff Oncology during the 4th quarter worth $108,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Cardiff Oncology by 50.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock worth $108,000 after buying an additional 11,497 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Cardiff Oncology by 24.9% during the second quarter. Invesco Ltd. now owns 23,795 shares of the company’s stock worth $75,000 after buying an additional 4,749 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Cardiff Oncology by 23.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock valued at $69,000 after acquiring an additional 4,232 shares during the period. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.